• Kester has announced the first and final close of its fourth fund, Kester Capital Fund IV, at its hard cap of £425 million.
• The fundraise lasted four months, was materially oversubscribed, and resulted in a single close driven by strong demand from existing and new institutional investors.
• Fund IV is a significant increase from Fund III, which closed with £200 million of third-party capital.
• Strong support came from blue-chip investors across the US, Europe and Asia, reflecting confidence in Kester’s thematic investment strategy and track record.
• Fund IV continues Kester’s focus on high-growth, high-potential companies in Technology and Life Sciences.
• The firm works with ambitious management teams to scale businesses and build category leaders.
• The close of Fund IV follows active investment activity over the past twelve months.
• Recent investments include Addresscloud (insurance risk intelligence), Re-flow (field service management software for critical infrastructure) and Evestia Clinical (global CRO for pharma and biotech).
• Kester has a strong performance track record, with four consecutive exits over 4x and eight consecutive exits over 3x.
• Its sector focus and value creation reputation have attracted a diverse global investor base including pension funds, endowments, family offices and asset managers.
• Adam Maidment stated that closing Fund IV at the hard cap reflects strong support for the firm’s strategy, team and investor outcomes.
• Cameron Crockett noted that Fund IV enables continued investment in the team and platform and supports partnerships with high-potential Technology and Life Sciences companies.
• The fundraise lasted four months, was materially oversubscribed, and resulted in a single close driven by strong demand from existing and new institutional investors.
• Fund IV is a significant increase from Fund III, which closed with £200 million of third-party capital.
• Strong support came from blue-chip investors across the US, Europe and Asia, reflecting confidence in Kester’s thematic investment strategy and track record.
• Fund IV continues Kester’s focus on high-growth, high-potential companies in Technology and Life Sciences.
• The firm works with ambitious management teams to scale businesses and build category leaders.
• The close of Fund IV follows active investment activity over the past twelve months.
• Recent investments include Addresscloud (insurance risk intelligence), Re-flow (field service management software for critical infrastructure) and Evestia Clinical (global CRO for pharma and biotech).
• Kester has a strong performance track record, with four consecutive exits over 4x and eight consecutive exits over 3x.
• Its sector focus and value creation reputation have attracted a diverse global investor base including pension funds, endowments, family offices and asset managers.
• Adam Maidment stated that closing Fund IV at the hard cap reflects strong support for the firm’s strategy, team and investor outcomes.
• Cameron Crockett noted that Fund IV enables continued investment in the team and platform and supports partnerships with high-potential Technology and Life Sciences companies.